The short answer
Waser and colleagues measured incretin receptors across rodent and human thyroid tissue. GLP-1 receptors are present in normal rat and mouse C-cells, and reach 100% incidence in rat C-cell hyperplasia and medullary thyroid carcinoma. No GLP-1 or GIP receptors were detected in normal human thyroid.
Key facts
- Study
- Waser 2011, Neuroendocrinology (PMID 21893952)
- Method
- In vitro receptor autoradiography
- Normal rodent C-cells
- GLP-1 receptors present
- Rat C-cell hyperplasia and MTC
- GLP-1R incidence 100%
- Normal human thyroid
- No GLP-1 or GIP receptors detected
- Human MTC, GLP-1R
- 27%
- Human MTC, GIP receptors
- Up to 89%, high density
Why receptor expression is the decisive question
The rodent effect was characterised as on-target: it proceeds through the GLP-1 receptor. An on-target effect requires the target. If human C-cells express the receptor at much lower density than rodent C-cells, the same drug would engage far less of the same pathway, and the rodent finding would not straightforwardly predict a human one.
What the measurements showed in rodents
GLP-1 receptors are expressed in C-cells of normal rat and mouse thyroid. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinoma, where incidence reaches 100%. GIP receptors are absent from normal rodent thyroid and from C-cell hyperplasia, but present in all rat medullary thyroid carcinomas.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What they showed in humans
No GLP-1 or GIP receptors were detected in normal human thyroid at all. Among human medullary thyroid carcinomas, 27% expressed GLP-1 receptors while up to 89% expressed GIP receptors at high density. TT cells, a human medullary thyroid carcinoma line, lack GLP-1 receptors and express GIP receptors.
The asymmetry that is rarely stated
The boxed warning concerns GLP-1 receptor agonists and derives from rodent data. In human medullary thyroid carcinoma, the abundantly expressed incretin receptor is GIP at up to 89%, while GLP-1 is the rarer one at 27%. That is a receptor distribution observation, not evidence of harm from anything, and it does not appear in most discussion of this warning.
What this does and does not license concluding
It provides a mechanistic reason the rodent finding might not extend to humans, a reason grounded in measurement rather than assertion. It does not demonstrate safety. Receptor autoradiography describes what is present in tissue; whether an exposure produces an outcome over years is an epidemiological question, answered separately and by different methods.
Why the label wording is careful
Regulatory labelling states that it is unknown whether these agents cause thyroid C-cell tumours in humans, and that the human relevance of the rodent findings has not been determined. That is an accurate description of the position: a serious rodent signal, a species difference with a plausible mechanistic basis, and no resolution from the toxicology itself.
Quick reference
| Tissue | GLP-1 receptors | GIP receptors |
|---|---|---|
| Normal rat/mouse thyroid C-cells | Present | Not detected |
| Rat C-cell hyperplasia and MTC | 100% incidence | Present in all rat MTC |
| Normal human thyroid | Not detected | Not detected |
| Human medullary thyroid carcinoma | 27% | Up to 89%, high density |
Frequently asked questions
Do human thyroids have GLP-1 receptors?
Waser 2011 detected no GLP-1 or GIP receptors in normal human thyroid, in contrast to normal rat and mouse C-cells where GLP-1 receptors are present.
Does that mean the drugs are safe for the thyroid?
No. It gives a mechanistic reason the rodent finding may not extend to humans. Whether an exposure produces an outcome is an epidemiological question answered by different methods.
Which incretin receptor is common in human MTC?
GIP, at up to 89% with high density. GLP-1 receptors appear in only 27%, the reverse of what the warning's framing suggests.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedWaser B et al., Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 2011 (PMID 21893952)pubmed.ncbi.nlm.nih.gov
- PubMedBjerre Knudsen L et al. Endocrinology 2010 (PMID 20203154)pubmed.ncbi.nlm.nih.gov
- PubMedRosol TJ, On-target effects of GLP-1 receptor agonists on thyroid C-cells. Toxicol Pathol 2013 (PMID 23471186)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Strongest Warning a Label CarriesA boxed warning is the most serious labelling a regulator applies. It does not mean a risk is proven - it means the consequence would be severe.
- The Hormone That Empties the Gallbladder, SuppressedCholecystokinin makes the gallbladder contract. GLP-1 suppresses cholecystokinin secretion - which is the identified mechanism behind the biliary events.
- What the Meta-Analysis EstablishedHe 2022 pooled randomised trials on gallbladder and biliary disease with GLP-1 receptor agonists. Why pooling was necessary for an outcome this infrequent.
- The Gallbladder Case Is Unusually CompleteObservation, then mechanism, then quantification. Most safety signals never get all three - which is why this one is worth studying as a template.
- What Happens to Bone When Load Comes OffBone responds to mechanical loading, so losing mass reduces the stimulus that maintains it. A 2025 critical appraisal examines what the medications add.